NanoMn®_COVID-19 A Prospective, Multicenter, Randomized, Placebo-controlled, Parallel-group, Double-blind Trial to Evaluate the Clinical Efficacy of NanoManganese® on Top of Standard of Care, in Adult Patients With Moderate to Severe Coronavirus Disease 2019 (COVID-19)

NCT05451654 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
7
Enrollment
INDUSTRY
Sponsor class

Stopped the number of patients recruited was not reached because covid cases were low

Conditions

Interventions

Sponsor

Medesis Pharma SA